title: Turning a corner on HIV neutralization?
abstract: HIV vaccine development has been hampered by the inability of conventional immunogens to elicit antibodies capable of neutralizing primary isolates of the virus. Recent studies using 'fusion-competent' immunogens that capture transitional intermediate structures of the functioning envelope protein suggest that this goal may now be achievable.
authors.affiliation: Montana Biotechnology Center, The University of Montana, Missoula, MT 59812, USA.
authors.forename: J H
authors.initials: JH
authors.lastname: Nunberg
authors.forename: K E
authors.initials: KE
authors.lastname: Follis
authors.forename: M
authors.initials: M
authors.lastname: Trahey
authors.forename: R A
authors.initials: RA
authors.lastname: LaCasse
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology*; D000818:Animals; D006678:HIV / Q000276:immunology*; D015699:HIV Envelope Protein gp120 / Q000276:immunology; D015658:HIV Infections / Q000517:prevention & control*; D006801:Humans; D009500:Neutralization Tests; D010446:Peptide Fragments / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology*
chemical_list: D016915:AIDS Vaccines; D015699:HIV Envelope Protein gp120; C059762:HIV envelope protein gp120 (305-321); D010446:Peptide Fragments; D014614:Vaccines, Synthetic